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Abstract
Panax ginseng is one of the most widely prescribed herbal medicines for the treatment of cancer, diabetes, chronic
inflammation, and neurodegenerative and cardiovascular diseases. Since the use of alternative medicines in combi-
nation with conventional therapy may increase the risk of unwanted interactions, we investigated the possible
genotoxicity of a water-soluble form of the dry root of P. ginseng (2.5, 5.0 or 10.0 mg/mL) and its ability to protect
against the genotoxicity of doxorubicin (DOX; 0.125 mg/mL) by using the Drosophila melanogaster wing somatic mu-
tation and recombination test (SMART) with standard and high-bioactivation crosses of flies. Panax ginseng was not
genotoxic at the concentrations tested, whereas DOX-induced genotoxicity in marker-heterozygous flies resulted
mainly from mitotic recombination. At low concentrations, P. ginseng had antirecombinogenic activity that was inde-
pendent of the concentration of extract used. Recombination events may promote cancer, but little is known about
the ability of P. ginseng to inhibit such recombination or modulate DNA repair mechanisms.
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Introduction
Plant products are being increasingly used as comple-
mentary or alternative medicines for the treatment for a va-
riety of diseases, including cancer (Meijerman et al., 2006),
although in many cases there is still only limited scientific
evidence for their therapeutic efficacy. The root of Panax
ginseng C. A. Meyer (Araliaceae), a common plant in east-
ern Asia, is widely used in Chinese natural medicine (Lee et
al., 2004; Yoshikawa et al., 2007). Panax ginseng is also
being increasingly prescribed in Korea, Japan and Western
countries for the treatment of cancer, diabetes, chronic in-
flammation, and neurodegenerative and cardiovascular dis-
eases (Yun, 1996; Radad et al., 2006). Several studies have
demonstrated the therapeutic potential of ginseng in the
central nervous system through its ability to improve lon-
gevity (Attele et al., 1999; Li et al., 2000) and cognitive
performance (Kennedy et al., 2004; Reay et al., 2005), as
well as its adaptogenic properties in contributing to the
equilibrium of the human body under prolonged stress
(Kumar et al., 1996).
Ginseng contains many physiologically important
constituents that include saponins, oils and phytosterol, car-
bohydrates and sugars, organic acids, nitrogenous sub-
stances, amino acids and peptides, vitamins and minerals
(iron, copper, zinc), and several enzymes (Hou, 1977; Attele
et al., 1999). Of the various compounds isolated from gin-
seng roots, the ginsenosides are known to have multiple
pharmacological activities (Deng and Zhang, 1991; Baek
et al., 2006; Wang et al., 2007). At the doses commonly
used, the dried roots and rhizomes of ginseng are not toxic
to rats, dogs and humans (Radad et al., 2006).
There is increasing interest in the identification of
herbal and dietary compounds that can prevent or reduce
the risks of cancer or serve as therapeutic agents (Rauscher
et al., 1998; Li et al., 2000). One result of these efforts is
that chemoprevention has emerged as a cost-effective
means of preventing mutagenesis and carcinogenesis, and
as a promising approach for minimizing the adverse effects
of human exposure to environmental carcinogens (Pool-
Zobel et al., 1997; Rauscher et al., 1998).
Doxorubicin (DOX), a broad-spectrum anthracycline
antibiotic, is genotoxic and carcinogenic but is still widely
used as an antitumor agent for the treatment of cancer
(Minotti et al., 2004). The potential usefulness of this drug
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is limited by the development of adverse effects such as
cardiotoxicity and nephrotoxicity. DOX may also be in-
volved in secondary malignancies. The main mechanisms
of action proposed for DOX include the inhibition of
topoisomerase II, DNA intercalation, free radical forma-
tion, reductive bioactivation of the quinine ring to a
semiquinone radical, DNA alkylation and cross-linking
(Gewirtz, 1999; Ramji et al., 2003; Navarro et al., 2006).
These mechanisms can result in the cleavage of DNA
which, if not repaired, may lead to mutations and chromo-
somal aberrations in tumors as well as in healthy cells
(Antunes and Takahashi, 1998; Gentile et al., 1998; Islaih
et al., 2005; Antunes et al., 2007; Costa and Nepomuceno,
2006; Fragiorge et al., 2007; Valadares et al., 2008).
We have used the Drosophila melanogaster (fruit fly)
wing somatic mutation and recombination test (SMART) as
a biological indicator of chemical genotoxicity or antigeno-
toxicity. This one-generation test, which is very efficient and
sensitive, is based on the ability of fruit flies to metabolize
certain procarcinogens to their reactive metabolites and has
been used to study the genotoxicity and antigenotoxicity of
various natural compounds (Idaomar et al., 2002; Laoha-
vechvanich et al., 2006; Silva et al., 2006; Fragiorge et al.,
2007; Mezzoug et al., 2007; Tellez et al., 2007; Valadares et
al., 2008). The wing SMART is based on the principle that a
loss of heterozygosity leads to the expression of recessive
marker genes in larval imaginal disk cells, thereby yielding
clones of mutant cells that can be identified as mosaic spots
on the wings (Graf et al., 1984, 1998). These spots can be
produced by mitotic recombination or mutations (deletions,
point mutations, specific types of translocation, etc.). The
analysis of two genotypes (one with structurally normal
chromosomes and another with a multiply inverted balancer
chromosome) allows the quantitative determination of the
recombinogenic activity of genotoxic compounds (Graf et
al., 1998; Spanó et al., 2001).
The identification of additional and more effective
antigenotoxic compounds may contribute to the develop-
ment of dietary supplements that could be useful in chemo-
therapy. Because the use of alternative medicines in combi-
nation with conventional therapy may increase the risk of
unwanted interactions in cancer patients (Meijerman et al.,
2006), in this work we used the wing SMART to investi-
gate the possible genotoxicity of three doses of a wa-
ter-soluble form of the dry root of P. ginseng and its ability
to protect against the genotoxicity of DOX. To our knowl-
edge the effects of ginseng on DOX genotoxicity have not
yet been studied in vitro or in vivo.
Materials and Methods
Chemical agents
The water-soluble form of the dry root of P. ginseng
C. A. Meyer (ginseng coreano, in Portuguese) was obtained
from Officinal Farmácia de Manipulação (Goiânia, GO,
Brazil). Doxorubicin (DOX, Doxina® - Eurofarma Labo-
ratórios Ltda., São Paulo, Brazil; CAS No. 23214-92-8)
was obtained from Hospital de Clínicas da Universidade
Federal de Uberlândia (Uberlândia, MG, Brazil) and dis-
solved in ultrapure water in the dark. Ultrapure water, used
as a negative control, was obtained from a MilliQ system
(Millipore, Vimodrone, Milan, Italy). All solutions were
freshly prepared in ultrapure water immediately before use.
Strains and crosses
For the wing SMART, three strains of D.
melanogaster [(i) the multiple wing hairs: y; mwh j; (2) the
flare-3: flr3/In(3LR)TM3, ri ppsep l(3)89Aa bx34e e BdS; and
(iii) the ORR; flare-3: ORR; flr3/In(3LR)TM3, ri ppsep
l(3)89Aa bx34e e BdS], and two crosses were used. The two
crosses consisted of a standard (ST) cross in which flare-3
females were mated with mwh males (Graf et al., 1989) and
a high bioactivation (HB) cross in which ORR; flare-3 fe-
males were mated with mwh males (Graf and van Schaik,
1992). The latter cross is highly sensitive to promutagens
and procarcinogens because of the increased level of cyto-
chrome P450 present in the ORR; flare-3 strain. Both
crosses produced experimental larval progeny that con-
sisted of marker-heterozygous (MH) flies (mwh +/+ flr3)
with phenotypically wild-type wings and balancer-hetero-
zygous (BH) flies (mwh +/+TM3, BdS) with phenotypically
serrate wings. Additional information about these strains
and crosses is provided elsewhere (Dapkus and Merrel,
1977; Hällström and Blanck, 1985; Graf et al., 1989; Graf
and van Schaik, 1992; Saner et al., 1996).
Larval feeding
After an 8 h mating period, the eggs were collected
from the two crosses and maintained in culture flasks con-
taining an agar-agar base (3% w/v) and a layer of fermenting
live baker’s yeast supplemented with sucrose. Third instar
larvae from these eggs were collected and transferred to
glass vials containing 1.5 g of mashed potato flakes
rehydrated with 5 mL of a solution containing the water solu-
ble form of the dry roots of P. ginseng (2.5, 5.0 or
10.0 mg/mL) alone or in association with DOX
(0.125 mg/mL). Negative (ultrapure water) and positive
(DOX 0.125 mg/mL) controls were included in these experi-
ments. The larvae were allowed to feed on the medium until
completion of their larval life (~48 h). The experiments were
done at 25 °C and a relative humidity of 60%-70%.
Analysis of adult flies
Adult flies were collected and stored in 70% ethanol.
The wings of MH flies were mounted on slides in Faure’s
solution and examined for spots by using a compound mi-
croscope at 400X magnification. The wings of BH flies
were mounted and analyzed whenever a positive response
was obtained in the MH progeny. Single spots resulted
from point mutations, chromosomal aberrations, or recom-
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bination events, whereas twin spots (mwh and flr3) were
produced by mitotic recombination between the proximal
marker flr3 and the centromere of chromosome 3. Only
mwh single spots were observed in the wings of BH flies.
The results obtained in MH and BH flies were used to as-
sess the recombinogenic potential of the water soluble form
of the dry root of P. ginseng and DOX (Frei et al., 1992;
Graf et al., 1992; Spanó et al., 2001).
Data evaluation and statistical analysis
For statistical evaluation, the multiple-decision pro-
cedure of Frei and Würgler (1988) was used and allowed
four diagnoses: +, positive; w+, weak positive; -, negative
and i, inconclusive. The frequencies of each type of mutant
clone per fly in a treated series were compared pair-wise
(i.e., negative control vs. Pg; DOX alone vs. DOX plus Pg)
using the conditional binomial test described by Kasten-
baun and Bowman (1970). For the final statistical analysis
of all positive outcomes, the non-parametric Mann-
Whitney U-test with α = β = 0.05 was used to exclude false
positive results (Frei and Würgler, 1995). The frequencies
of clone induction per 105 cells were used to determine the
recombinogenic activity based on the following parame-
ters: mutation frequency (FM) = frequency of clones in BH
flies/frequency of clones in MH flies, recombination fre-
quency (FR) = 1- FM, frequency of the total number of spots
(FT) = total number of spots in MH flies (considering mwh
and flr3 spots)/number of flies, frequency of mutation = FT
x FM and frequency of recombination = FT x FR (Santos et
al., 1999; Sinigaglia et al., 2006). Based on the con-
trol-corrected spot frequencies per 105 cells the percentage
of inhibition by P. ginseng was calculated as (DOX alone -
P. ginseng plus DOX/DOX alone) x 100 (Abraham, 1994).
Results
Tables 1 and 2 show the wing SMART results for the
chronic treatment of larvae with P. ginseng alone (2.5, 5.0
or 10.0 mg/mL) or in combination with DOX
(0.125 mg/mL) using flies from ST and HB crosses, respec-
tively. Larvae from both crosses were treated under identi-
cal conditions. Negative (ultrapure water) and positive
(DOX 0.125 mg/mL) controls were included in each exper-
iment. For statistical evaluation, the results from flies
treated with P. ginseng were compared with data from the
corresponding negative controls, whereas the results from
flies treated with P. ginseng plus DOX were compared with
data from the corresponding positive controls. Whenever
there was a positive effect on the total number of spots in
the MH progeny, the BH progeny were also analyzed.
There were no significant differences in the fre-
quency of mutant spots between flies treated with 2.5, 5.0
or 10.0 mg of P. ginseng/mL and the negative control in ST
cross MH flies (Table 1) and HB cross MH flies (Table 2).
DOX (positive control) caused significant induction of all
categories of spots in both the ST and HB crosses (Tables 1
and 2).
In ST cross MH flies, simultaneous treatment with
2.5 or 5.0 mg of P. ginseng/mL only weakly inhibited the
increase in the total number of total spots caused by DOX
whereas treatment with 10 mg of P. ginseng/mL did not al-
ter the frequency of mutant spots (Table 1). In HB cross
MH flies, simultaneous treatment with 2.5 or 10.0 mg of P.
ginseng/mL reduced the total number of spots produced by
DOX alone (Table 2). The frequency of mutant spots pro-
duced by DOX was not altered by simultaneous treatment
with 2.5 or 5.0 mg of P. ginseng/mL in ST cross BH flies
(Table 1), or 2.5 or 10.0 mg of P. ginseng/mL in HB cross
BH flies (Table 2). Thus, P. ginseng did not interfere with
the frequencies of DOX-induced spots of mutational (genic
and chromosomal) origin.
The frequencies of clone induction per 105 cells in
MH and BH flies treated with DOX alone or with P. gin-
seng plus DOX were used to assess the mutagenic and
recombinogenic potential of P. ginseng. The genotoxicity
in MH flies was attributable mainly to mitotic recombina-
tion. The dry root of P. ginseng had antirecombinogenic ac-
tivity that was not dose-dependent.
Discussion
The wing SMART is rapid, sensitive and inexpensive
assay for investigating the mutagenic and recombinogenic
properties of chemicals, natural products and complex mix-
tures. This assay is also suitable for studying the mutagenic,
antimutagenic and recombinogenic activities of drugs dur-
ing multi-drug therapy (Graf et al., 1984; Spanó et al.,
2001).
In this study, we examined the effects of three con-
centrations of P. ginseng (2.5, 5.0 or 10.0 mg/mL) in the
wing SMART. Panax ginseng alone was not genotoxic in
the ST and HB crosses. Simultaneous treatment with P.
ginseng reduced the total number of spots produced by
DOX in ST cross and HB cross MH flies, although the con-
centrations required for this varied between the crosses.
DOX was studied here because of its widespread use
in cancer chemotherapy. A single concentration of DOX
(0.125 mg/mL) was used in the wing SMART and signifi-
cantly increased the number of mutant single spots and twin
spots in ST and HB crosses. In addition to its mutagenic ac-
tivity, DOX also has recombinogenic activity so that the
frequency of twin spots reflected DOX-induced somatic re-
combination. These findings agree with other reports and
show that DOX selectively induces homologous recombi-
nation when compared with mutational events in D.
melanogaster somatic cells (Lehmann et al., 2003; Costa
and Nepomuceno, 2006; Fragiorge et al., 2007; Valadares
et al., 2008).
The HB cross has constitutively high levels of cyto-
chrome P450 and is characterized by a high sensitivity to
promutagens and procarcinogens (Spanó et al., 2001).
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Comparison of the results obtained with the ST and HB
crosses showed that the elevated cytochrome P450 activity
in HB flies influenced the genotoxicity of DOX and that of
the combined treatments, with a greater frequency of mu-
tant spots in these flies, as also reported by Valadares et al.
(2008). The greater genotoxicity of DOX in HB flies proba-
bly reflects the rapid one-electron reduction of this com-
pound to its semiquinone free radical by cytochrome P450
(Goeptar et al., 1993).
Many herbal and dietary products modulate cyto-
chrome P450 activity. Gurley et al. (2002) used single-time
point phenotypic metabolic ratios to determine whether
long-term supplementation of St John’s wort, garlic oil, P.
ginseng and Ginkgo biloba affected CYP1A2, CYP2D6,
CYP2E1 and CYP3A4 activities in humans; no significant
effect was observed for P. ginseng. In agreement with this,
Gurley et al. (2005) observed that the concomitant inges-
tion of P. ginseng with prescription medications in elderly
patients resulted in only slight inhibition (7%) of CYP2D6
activity.
Ginseng extract significantly decreases DNA synthe-
sis and increases the rate of DNA excision repair synthesis
in V79 Chinese hamster lung cells (Rhee et al., 1991), in
addition to its ability to attenuate inflammation-mediated
carcinogenesis (Hofseth and Wargovich, 2007). These
mechanisms can reduce tumor growth and improve the
prognosis in cancer patients (Wang et al., 2007). The bene-
ficial effects of ginseng and its main constituents during
chemotherapy are probably related to their ability to mini-
mize the adverse effects of antineoplastic drugs. Recent
findings in vivo and in vitro have shown that ginseng par-
tially protects against DOX-induced testicular toxicity
(Kang et al., 2002), significantly attenuates the effects of
DOX-induced heart failure in rats (You et al., 2005), and
reduces cisplatin-induced nephrotoxicity in cultured renal
proximal tubular epithelial cells (Baek et al., 2006). In con-
trast, little is known about the effects of ginseng and its
compounds when administered in combination with
chemotherapeutic drugs.
Dietary supplementation of ginseng protects against
oxidative damage in vitro and in vivo, from acute oxidative
stress in cardiomyocytes to heart perfusion injury (Maffei-
Facino et al., 1999; Shao et al., 2004). Yance and Sagar
(2006) reported that P. ginseng has antiangiogenic activity
and anticancer activities that are mediated by multiple in-
terdependent processes, including changes in gene expres-
sion, signal processing and enzymatic activities. Although
the mechanisms of action of the more than 60 ginsenosides
isolated from Panax species remain poorly understood,
studies of these compounds and their effects on tumor cells
are of interest since several ginsenosides efficiently inhibit
cell growth and the proliferation of human cancer cell lines
(Wang et al., 2007).
Total ginseng extracts or aqueous fractions of P. gin-
seng show antimutagenic effects that include a reduction in
the frequency of radiation-induced DNA breaks in murine
lymphocytes and protection against 137Cs-induced micro-
nuclei in human lymphocytes (Rhee et al., 1991; Kim et al.,
1996; Lee et al., 2004). Ginseng-treated Swiss white mice
show a significant reduction in the frequencies of chromo-
somal aberrations and micronuclei induced by benzo[a]py-
rene (Panwar et al., 2005). Ginsan, which itself is not
mutagenic, decreases the frequency of micronucleated
polychromatic erythrocytes induced by gamma radiation in
bone marrow cells of C57BL/6 male mice (Ivanova et al.,
2006). Similarly, the ginsenoside Rh2 enhances the anti-
tumor activity and decreases the genotoxicity of cyclophos-
phamide in mice (Wang et al., 2006). Ginseng has powerful
antioxidant (Cho et al., 2008) and antimutagenic (Geetha et
al., 2006; Ivanova et al., 2006) properties, although the
mechanisms of these protective effects remain to be eluci-
dated. Geetha et al. (2006) reported that ginseng extracts
protected against H2O2-induced mutagenesis in Salmonella
typhimurium strain TA100, and against mutagenesis pro-
duced by 4-nitroquinoline-N-oxide in S. typhimurium
strains TA98 and TA100 in the Ames test; however, the ex-
tract was unable to inhibit the damage induced by tert-butyl
hydroperoxide in strain TA102 which is highly sensitive to
reactive oxygen species. The authors concluded that the
protection provided by the ginseng extract against 4-nitro-
quinoline-N-oxide and H2O2-induced mutagenicity in
strains TA98 and TA100 was attributable mainly to the ex-
tracts ability to promote DNA repair rather than its antioxi-
dant effects.
Our results indicate that P. ginseng is not genotoxic in
somatic cells of D. melanogaster, and that at low concen-
trations it protects against the genotoxicity of DOX. Inhibi-
tors of mutagenesis often act through multiple mechanisms
or can interact with other inhibitors (De Flora and Ramel,
1988). The mechanisms by which P. ginseng protects cells
against DOC-induced genotoxicity were not examined here
but could involve direct interaction of the extract constitu-
ents with DOX, resulting in an antimutagenic effect, and/or
an antioxidant action through radical scavenging or the ac-
tivation of intracellular antioxidant enzymes. Although ho-
mologous recombination causes rearrangements of DNA
that can promote cancer, little was known about the ability
of P. ginseng to inhibit recombination or modulate DNA re-
pair mechanisms. More data are required on the dose-
response relationship of P. ginseng and the potential toxici-
ties of combinations with chemotherapeutic drugs or radia-
tion before this product can be recommended for cancer
therapy.
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